EOC Pharma Group

EOC Pharma Group

Empowering cancer care in China through a robust network of global partnerships, innovative drug development, and exceptional local expertise.

Founded 2015 Series C Total: $532.00M Biopharma, Biotechnology +3

EOC Pharma Group is an integrated biopharmaceutical company founded in 2015 that is dedicated to empowering cancer care in China. With a robust network of global partnerships, innovative drug development, and exceptional local expertise, the company aims to revolutionize oncology treatment in China. EOC Pharma employs a licensing model to enhance its innovative pipeline by incorporating partner molecules into EOC’s local manufacturing, clinical development, regulatory filing, and commercialization processes. At the heart of EOC's operation is its 8,000 square meter cGMP manufacturing facility in Taizhou, China Medical City. The company's last investment was a CNY500.00M Series C investment on 02 December 2019, with participation from prominent investors including TF Capital, Hanne Capital, 盈科创新资产管理有限公司 (Innovation Asset Management Co., Ltd.), Tigermed, and BioVenture. EOC Pharma has a portfolio of seven novel products from global biopharmaceutical partners, with the potential to be first- and best-in-class in their respective segments. The company has already obtained four Class I innovative drug CTA approvals and commenced clinical studies of four lead products in China, demonstrating its commitment to advancing cancer treatment. Supported by a team of entrepreneurs and consultants with international backgrounds and extensive industry experience, EOC Pharma is strategically positioned to harness forward-looking licensing and generate product opportunities within its integrated platform. This strategy is poised to establish EOC at the forefront of oncology innovation in China, reflecting its aspirations to be a key player in the global oncology market.

Funding Stage	Amount	Investors	Lead Investors	Date
Series C	CNY500.00M	5	TF Capital, Hanne Capital +3	02 Dec 2019
Series B	$32.00M	3	Sequoia Capital, H&Q Asia Pacific +1	07 Nov 2017

Funding Stage

Amount

Investors

Lead Investors

Date

Series C

CNY500.00M

TF Capital, Hanne Capital +3

02 Dec 2019

Series B

$32.00M

Sequoia Capital, H&Q Asia Pacific +1

07 Nov 2017

FAQ About EOC Pharma Group

Empowering cancer care in China through a robust network of global partnerships, innovative drug development, and exceptional local expertise.

EOC Pharma Group was founded in 2015.

EOC Pharma Group operates in Biopharma, Biotechnology, Health Care, Manufacturing and Pharmaceutical. Its work centres on Biopharmaceutical, Oncology, Innovative drug development and Global partnerships.

EOC Pharma Group has completed 2 funding rounds, raising a total of $532.00M. The latest funding stage is Series C.

Top alternatives and competitors to EOC Pharma Group include Spectrum Pharmaceuticals, Innovent Biologics, Adlai Nortye, CASI Pharmaceuticals, Inc., Xynomic Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

EOC Pharma Group and Spectrum Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About EOC Pharma Group

Funding Rounds & Investors (2)

EOC Pharma Group Alternatives & Competitors

FAQ About EOC Pharma Group